Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

Review question What are the effects (benefits and harms) of palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children? Background RSV is the main cause of acute ...

To help keep all respiratory virus transmission and infection rates low and to manage positive cases when they arise, please be aware of the following CDC-based recommendations. Flu, COVID-19, and ...

Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infections for which effective treatment options remain limited. Herein, we employed a computational structure-based ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...

Introduction Respiratory Syncytial Virus (RSV) is a principal etiological agent of acute lower respiratory tract infections (LRTIs) in infants and young children, contributing substantially to ...